|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Aging (chronic age-related diseases); ii. metabolic (hyperglycemia advanced glycation end products and its receptor (AGE/RAGE) interactions and hyperinsulinemia-insulin resistance (a linking linchpin); iii. oxidative stress (reactive oxygen-nitrogen species); iv. inflammation (peripheral macrophage and central brain microglia); v. vascular (macrovascular accelerated atherosclerosis-vascular stiffening and microvascular NVU/neuroglial remodeling) with resulting impaired cerebral blood flow.
|
31569571 |
2019 |
|
Atherosclerosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis.
|
18279705 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Soluble receptor for advanced glycation end products RAGE (sRAGE), a secretory form of RAGE, plays an important role in suppressing RAGE signals that induce pro-inflammatory gene activation in a range of inflammatory diseases, such as Alzheimer's disease, complications of diabetes mellitus and atherosclerosis.
|
23708564 |
2013 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
RAGE has been extensively implicated in inflammatory states such as atherosclerosis, but the role of S100A12 as its ligand is less clear.
|
19875725 |
2010 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands.
|
10082470 |
1999 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities Study.
|
26083729 |
2015 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The receptor for advanced glycosylation end products (RAGE) has been widely linked to diabetic atherosclerosis, but its effects on coronary artery disease (CAD) and ischemic stroke (IS) remain controversial.
|
27930580 |
2016 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation.
|
20372816 |
2010 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Interestingly, the accelerated atherosclerosis could be prevented by RAS inhibition, or markedly reduced by RAGE blockade, probably through anti-inflammatory and antioxidative effects.
|
19939336 |
2009 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
LHGDN |
RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
|
15155381 |
2004 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
LHGDN |
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.
|
18079965 |
2008 |
|
Atherosclerosis
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
|
18777492 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
RGD |
High expression of AGE and RAGE in the livers and arteries of rats with NASH may contribute to the pathogenesis of NASH and early atherosclerosis.
|
20835270 |
2010 |